The venture fund is an early stage investor in emerging life science technologies that was founded in 2003 and is based in Washington, with additional offices in New York City and San Diego. The firm closed its fourth fund in 2015 at $62.8 million. The firm seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2019, a China-based firm sponsored by the local municipal government manages 2 funds that associated with their local incubator: one USD fund of $100MM and one RMB fund of $1,000MM, and is open to global in-licensing opportunities.

The firm focuses on Class II and Class III medical devices at the development stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to stroke, cardiovascular disease, eye disease, and medical robots. Currently, the firm is not interested in the IVD sector.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a pharmaceutical company is looking to make investments around $3 million in companies in the life science space. The firm could make as many as 2-3 investment over the next year and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities.

The firm is currently looking for companies developing therapeutics and is open to small molecules, biologics, and cell/gene therapy. The team is more interested in companies working with single assets although they can consider platform technologies. Indications of interest include Oncology, Inflammation, Orphan diseases, Critical care, Ophthalmology and Autoimmune diseases. The firm tends to be agnostic though and in spite of these focuses, is willing to look at most projects. The team looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The firm looking for privately held companies and prefers companies with experienced management teams in place. The team looks to act as a value-added investor through their strategic alignment with their parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA  has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4 million. The firm plans to invest in 2-3 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences.  The firm is primarily focused on clinical stage biotech opportunities, and will consider any indication area.  The firm prefers to invest in platform technologies rather than single asset companies.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.  For therapeutics, Excel looks for companies that are developing platform technologies but have a clear plan on moving the lead program forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.